AbbVie hep C combo fast-tracked in U.S. and EU; Merck's Gardasil wins new indication in Europe;

> AbbVie's ($ABBV) all-oral hep C combo has won expedited assessment in both the U.S. and the EU. Report | Article

> Europe has approved Merck's ($MRK) Gardasil vaccine to prevent anal cancer. Report

> Bristol-Myers Squibb's ($BMY) "The Pink Drive" campaign took bronze at the Goafest's Abby awards. Story

> Takeda and Affymax ($AFFY) have terminated their collaboration and license agreement on anemia drug Omontys and will withdraw their NDA. More (sub. req.)

> Roche's ($RHHBY) Gazyvaro has won Swiss approval for the therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). Release

> U.K. cost watchdog NICE has given its recommendation to Sucampo Pharmaceuticals' constipation med, Amitiza. Release

> Boehringer Ingelheim has earned The Information Standard certification, commissioned by England's National Health Service, for the quality of its healthcare information. Report

And Finally... U.S. submission stumbled at the Lions Health Festival. More

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.